[go: up one dir, main page]

WO2017156423A3 - Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever - Google Patents

Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever Download PDF

Info

Publication number
WO2017156423A3
WO2017156423A3 PCT/US2017/021842 US2017021842W WO2017156423A3 WO 2017156423 A3 WO2017156423 A3 WO 2017156423A3 US 2017021842 W US2017021842 W US 2017021842W WO 2017156423 A3 WO2017156423 A3 WO 2017156423A3
Authority
WO
WIPO (PCT)
Prior art keywords
filovirus
treatment
hemorrhagic fever
protective antibody
antibody cocktails
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/021842
Other languages
French (fr)
Other versions
WO2017156423A2 (en
Inventor
Mohammad Javad Aman
Frederick Wayne Holtsberg
Laurence Mitchell ZEITLIN
Zachary Asa BORNHOLDT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mapp Biopharmaceutical Inc
Integrated BioTherapeutics Inc
Original Assignee
Mapp Biopharmaceutical Inc
Integrated BioTherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapp Biopharmaceutical Inc, Integrated BioTherapeutics Inc filed Critical Mapp Biopharmaceutical Inc
Publication of WO2017156423A2 publication Critical patent/WO2017156423A2/en
Publication of WO2017156423A3 publication Critical patent/WO2017156423A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This disclosure provides a method for preventing, treating, or managing a filovirus infection in a subject, where the method includes administering to a subject in need thereof an effective amount of at least two anti-filovirus glycoprotein antibodies or antigen-binding fragments thereof where at least one of the antibodies or fragments binds to its orthologous filovirus glycoprotein epitope on two or more filovirus species or strains.
PCT/US2017/021842 2016-03-11 2017-03-10 Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever Ceased WO2017156423A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662307118P 2016-03-11 2016-03-11
US62/307,118 2016-03-11
US201662368688P 2016-07-29 2016-07-29
US62/368,688 2016-07-29

Publications (2)

Publication Number Publication Date
WO2017156423A2 WO2017156423A2 (en) 2017-09-14
WO2017156423A3 true WO2017156423A3 (en) 2017-10-19

Family

ID=59789746

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/021842 Ceased WO2017156423A2 (en) 2016-03-11 2017-03-10 Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever

Country Status (1)

Country Link
WO (1) WO2017156423A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190240328A1 (en) * 2016-09-24 2019-08-08 The Trustees Of The University Of Pennsylvania Novel humanized anti-ebola antibodies useful in preventing ebola infections
CA3053305A1 (en) 2017-02-17 2018-08-23 Mapp Biopharmaceutical, Inc. Monoclonal antibodies and cocktails for treatment of ebola infections
EP3583122A4 (en) * 2017-02-17 2020-11-11 Mapp Biopharmaceutical, Inc. MONOCLONAL ANTIBODIES AND COCKTAILS FOR THE TREATMENT OF EBOLA INFECTION

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120014958A1 (en) * 2008-06-25 2012-01-19 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
US20150232556A1 (en) * 2012-09-19 2015-08-20 Innate Pharma Kir3dl2 binding agents
WO2015200522A2 (en) * 2014-06-25 2015-12-30 Integrated Biotherapeutics, Inc. Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species
WO2016069627A1 (en) * 2014-10-28 2016-05-06 Integrated Biotherapeutics, Inc. Non-human primate-derived pan-ebola and pan-filovirus monoclonal antibodies directed against envelope glycoproteins
WO2016145385A2 (en) * 2015-03-11 2016-09-15 Integrated Biotherapeutics, Inc. Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails
WO2016179511A1 (en) * 2015-05-07 2016-11-10 Mapp Biopharmaceutical, Inc. Monoclonal antibody cocktails for treatment of ebola infections
US20170088606A1 (en) * 2013-06-03 2017-03-30 Albert Einstein College Of Medicine, Inc. Therapy for filovirus infection

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120014958A1 (en) * 2008-06-25 2012-01-19 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
US20150232556A1 (en) * 2012-09-19 2015-08-20 Innate Pharma Kir3dl2 binding agents
US20170088606A1 (en) * 2013-06-03 2017-03-30 Albert Einstein College Of Medicine, Inc. Therapy for filovirus infection
WO2015200522A2 (en) * 2014-06-25 2015-12-30 Integrated Biotherapeutics, Inc. Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species
WO2016069627A1 (en) * 2014-10-28 2016-05-06 Integrated Biotherapeutics, Inc. Non-human primate-derived pan-ebola and pan-filovirus monoclonal antibodies directed against envelope glycoproteins
WO2016145385A2 (en) * 2015-03-11 2016-09-15 Integrated Biotherapeutics, Inc. Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails
WO2016179511A1 (en) * 2015-05-07 2016-11-10 Mapp Biopharmaceutical, Inc. Monoclonal antibody cocktails for treatment of ebola infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MURIN, CD ET AL.: "Structures of protective antibodies reveal sites of vulnerability on Ebola virus", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., vol. 111, no. 48, 2 December 2014 (2014-12-02), pages 17182 - 17187, XP055321303 *
SUNDLING, C ET AL.: "Single- cell and deep sequencing of IgG-switched macaque B cells reveal a diverse immunoglobulin repertoire following immunization", JOURNAL OF IMMUNOLOGY, vol. 192, no. 8, 15 April 2015 (2015-04-15), pages 3637 - 3644, XP055432919 *

Also Published As

Publication number Publication date
WO2017156423A2 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
WO2016145385A3 (en) Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
MX2020006213A (en) ANTI-TREM2 ANTIBODIES AND RELATED METHODS.
WO2015143123A3 (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
WO2016029073A3 (en) Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
WO2015200806A3 (en) Humanized anti-tau antibodies
IL291545A (en) Antibodies against ctla4, antibody fragments, their immunoconjugates and their uses
WO2016201389A3 (en) Anti-cd33 antibodies and methods of use thereof
WO2016201388A3 (en) Anti-cd33 antibodies and methods of use thereof
MX2018009498A (en) Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes.
MY187262A (en) Anti-lag3 antibodies and antigen-binding fragments
WO2016062722A8 (en) Combination
WO2014186622A3 (en) Methods of treatment for guillain-barre syndrome
TW201613575A (en) Treatment of polybacterial infections
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
ES2776179T3 (en) Antibodies directed against surface determinants of S. aureus
WO2015120097A3 (en) Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
WO2018089807A3 (en) Anti-cd46 antibodies and methods of use
WO2016057683A3 (en) Novel anti-nodal antibodies and methods of using same
WO2020023644A3 (en) Antibody directed against s. aureus clumping factor a (clfa)
PH12021552903A1 (en) Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
MX2017004970A (en) Antibodies that bind to ccr6 and their uses.
WO2017075188A3 (en) Methods of using anti-alpha toxin antibody
EP4273165A3 (en) Interferon beta antibodies and uses thereof
UY36820A (en) SPECIFIC MONOCLONAL ANTIBODIES FOR ANTIGEN P OF HUMAN SYNCHRIRY RESPIRATORY VIRUS (VRSH), PRODUCED AND SECRETED BY CELLULAR HYBRIDIDES, USEFUL FOR DETECTION AND DIAGNOSIS OF INFECTION CAUSED BY VRS

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17764204

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17764204

Country of ref document: EP

Kind code of ref document: A2